Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 844.77B +54.7% |
| Revenue (ttm) | 64.37B +49.6% |
| Net Income | 21.58B +93.6% |
| EPS | 24.07 +94.8% |
| Shares Out | n/a |
| PE Ratio | 39.14 |
| Forward PE | 27.85 |
| Dividend | 5.24 (0.55%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 960.00 |
| Day's Range | n/a |
| 52-Week Range | 600.00 - 1,010.00 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
An Investor's Guide to Intangible Assets
Although not always easy to quantify, intangible assets are one of the primary sources of strong competitive advantages for businesses and a key source of economic moats. Key Takeaways Intangible asse...
Eli Lilly announces FDA approves additional indication for Jaypirca
Eli Lilly (LLY) and Company announced that the U.S. Food and Drug Administration FDA has approved an additional indication for Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, for the treatm...
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtob...
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs...
Wedbush downgrades Foghorn on end of Lilly collaboration
Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10, after the company and Eli Lilly (LLY) elected not to advance FHD-909…
Foghorn Therapeutics downgraded at Citizens after FHD-909 discontinuation
As previously reported, Citizens analyst Silvan Tuerkcan downgraded Foghorn Therapeutics (FHTX) to Market Perform from Outperform after the company and partner Eli Lilly (LLY) announced the discontinu...
Trump Medicare drug pricing model may apply to only four companies after exemptions
A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting companies that signed separate "most favored nation" pricing agre...
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce
Foghorn Therapeutics (FHTX) announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909, Foghorn and Lilly (LLY) have decided not to advance the…
Eli Lilly’s Foundayo shows reduction in type 2 diabetes and cardiovascular risk
Eli Lilly (LLY) announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo – orforglipron – was associated with significant reductions in predicted 10-year risk of type 2 diabetes and…
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research...
Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study
Eli Lilly (LLY) announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo – orforglipron – vs. titrated insulin glargine in adults with type…
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-...
Lilly's new weight loss combo drug outperforms tirzepatide in latest trial
Eli Lilly reported positive results from a study following EloraTZP, its experimental combo weight loss drug, noting that patients lost an average of 23.3% of their body weight.
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Lilly says participants on EloraTZP lost up to average 23.3% of weight in study
Eli Lilly (LLY) announced “positive” results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP. Eloralintide alone reduced body weight by up to an average of 28.6…
Eli Lilly announces results of Phase 2b trial of EloraTZP
Eli Lilly (LLY) and Company announced results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist,...
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk fo...
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 dia...
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% co...
A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study
A drug combination studied in people with Type 2 diabetes lowered blood sugar and helped people lose more weight than with Zepbound alone.
Eli Lilly says ebglyss met endpoints in Phase 3b ADtouch study
Eli Lilly (LLY) and Company announced that ebglyss monotherapy met its primary and secondary endpoints at Week 16 in the Phase 3b ADtouch study, showing significant and rapid improvements in…
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as ea...
Eli Lilly and Company Slides: Investor presentation
Eli Lilly and Company has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Eli Lilly reports results from TRIUMPH-2 Phase 3 trial
Eli Lilly (LLY) and Company announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon tr...